New imaging paradigms in drug development: the PET imaging approach

Jan Marik; Sandra M Sanabria Bohorquez; Simon-Peter Williams; Nicholas van Bruggen

doi:10.1016/j.ddtec.2011.11.004

New imaging paradigms in drug development: the PET imaging approach

Drug Discov Today Technol. 2011 Summer;8(2-4):e63-9. doi: 10.1016/j.ddtec.2011.11.004.

Authors

Jan Marik¹, Sandra M Sanabria Bohorquez², Simon-Peter Williams², Nicholas van Bruggen²

Affiliations

¹ Genentech Research and Early Development (gRED), Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address:marik.jan@gene.com.
² Genentech Research and Early Development (gRED), Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

PMID: 24990264
DOI: 10.1016/j.ddtec.2011.11.004

Abstract

Molecular imaging is becoming an indispensable part of clinical drug development. The presented review highlights few state-of-the-art examples that serve to illustrate specific points and discuss future directions of the use of positron emission tomography (PET) imaging in various phases of clinical drug development.: